BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Historical Holders from Q1 2014 to Q3 2025

Symbol
BMRN on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
194M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
179M
Holdings value
$9.71B
% of all portfolios
0.009%
Grand Portfolio weight change
0%
Number of holders
567
Number of buys
293
Number of sells
-269
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 10.8% $1.3B 20.6M BlackRock, Inc. 31 Mar 2025
PRIMECAP MANAGEMENT CO/CA/ 8.24% $907M 15.8M PRIMECAP MANAGEMENT CO/CA/ 30 Jun 2025
Capital Research Global Investors 4.8% -28.6% $576M -$242M 9.15M -29.6% Capital Research Global Investors 31 Mar 2025
VIKING GLOBAL INVESTORS LP 4.3% -35% $451M -$215M 8.32M -32.3% VIKING GLOBAL INVESTORS LP 30 Sep 2025

Institutional Holders of BIOMARIN PHARMACEUTICAL INC - Common Stock, par value $0.001 per share (BMRN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 179M $9.71B -$264M $54.16 567
2025 Q2 185M $10.1B +$90.4M $54.97 576
2025 Q1 181M $12.8B -$83.6M $70.69 576
2024 Q4 183M $12B +$135M $65.73 536
2024 Q3 180M $12.7B -$377M $70.29 545
2024 Q2 185M $15.2B -$88.8M $82.33 555
2024 Q1 187M $16.3B +$52.1M $87.34 550
2023 Q4 186M $17.9B +$422M $96.42 540
2023 Q3 182M $16.1B +$288M $88.48 513
2023 Q2 179M $15.5B -$55.8M $86.68 548
2023 Q1 179M $17.4B -$353M $97.24 544
2022 Q4 183M $18.9B +$57.1M $103.49 570
2022 Q3 182M $15.5B +$266M $84.77 535
2022 Q2 179M $14.8B +$142M $82.87 525
2022 Q1 178M $13.7B +$56M $77.10 543
2021 Q4 177M $15.6B +$125M $88.35 539
2021 Q3 176M $13.6B +$49.7M $77.29 498
2021 Q2 176M $14.7B -$129M $83.44 510
2021 Q1 178M $13.4B -$324M $75.51 513
2020 Q4 182M $16B +$294M $87.69 519
2020 Q3 180M $13.7B -$318M $76.08 487
2020 Q2 181M $22.3B +$749M $123.34 516
2020 Q1 177M $14.9B +$286M $84.50 489
2019 Q4 173M $14.7B +$54M $84.55 454
2019 Q3 174M $11.7B -$330M $67.40 427
2019 Q2 178M $15.2B +$229M $85.65 471
2019 Q1 178M $15.8B -$79.1M $88.83 475
2018 Q4 179M $15.3B -$187M $85.15 459
2018 Q3 181M $17.5B -$163M $96.97 449
2018 Q2 183M $17.2B +$243M $94.20 440
2018 Q1 180M $14.6B +$188M $81.07 421
2017 Q4 178M $15.8B +$224M $89.17 431
2017 Q3 175M $16.3B +$328M $93.07 407
2017 Q2 171M $15.6B +$225M $90.82 423
2017 Q1 169M $14.8B +$900M $87.78 411
2016 Q4 169M $14B +$56.8M $82.84 404
2016 Q3 168M $15.6B +$821M $92.52 419
2016 Q2 160M $12.4B -$243M $77.80 386
2016 Q1 162M $13.4B +$50M $82.48 379
2015 Q4 161M $16.9B +$165M $104.76 381
2015 Q3 159M $16.8B +$117M $105.32 386
2015 Q2 158M $21.6B +$148M $136.78 390
2015 Q1 157M $19.5B +$1.28B $124.62 374
2014 Q4 148M $13.4B +$130M $90.40 338
2014 Q3 148M $10.7B +$238M $72.16 312
2014 Q2 145M $8.99B -$244M $62.21 319
2014 Q1 148M $10.1B +$481M $68.21 309